Assuntos
Infecções Bacterianas/veterinária , Doenças dos Bovinos/microbiologia , Endometrite/veterinária , Infecções por Herpesviridae/veterinária , Herpesvirus Bovino 4 , Infecções Tumorais por Vírus/veterinária , Animais , Infecções Bacterianas/complicações , Infecções Bacterianas/epidemiologia , Bovinos , Doenças dos Bovinos/epidemiologia , Endometrite/epidemiologia , Endometrite/microbiologia , Feminino , Infecções por Herpesviridae/complicações , Infecções por Herpesviridae/epidemiologia , Período Pós-Parto , Infecções Tumorais por Vírus/complicações , Infecções Tumorais por Vírus/epidemiologiaAssuntos
Doenças dos Bovinos/diagnóstico , Criptosporidiose/veterinária , Cryptosporidium/isolamento & purificação , Animais , Animais Recém-Nascidos , Bovinos , Doenças dos Bovinos/epidemiologia , Criptosporidiose/diagnóstico , Criptosporidiose/epidemiologia , Cryptosporidium/classificação , Reservatórios de Doenças/veterinária , Inglaterra/epidemiologia , Fezes/parasitologia , Análise Multivariada , Contagem de Ovos de Parasitas/veterinária , País de Gales/epidemiologiaAssuntos
Anticorpos Antivirais/sangue , Doença das Mucosas por Vírus da Diarreia Viral Bovina/epidemiologia , Vírus da Diarreia Viral Bovina/imunologia , Leite/imunologia , Complicações Infecciosas na Gravidez/veterinária , Fatores Etários , Animais , Bovinos , Inglaterra/epidemiologia , Feminino , Leite/microbiologia , Gravidez , Complicações Infecciosas na Gravidez/epidemiologia , Estudos SoroepidemiológicosRESUMO
Twenty-one young calves with maternally derived antibody to bovine respiratory syncytial virus (BRSV) were divided into three groups of seven, each group balanced for BRSV antibody titre. The calves had no evidence of previous exposure to BRSV. The calves in one group were given a single dose of a monovalent modified live BRSV vaccine; the calves in the second group were given a single dose of an inactivated combined BRSV, parainfluenza virus type 3, Mannheimia haemolytica vaccine and the calves in the third group were left as unvaccinated controls. Three weeks after the single doses of vaccine, all the calves were challenged with BRSV. The clinical signs of disease were mild, and virus excretion was limited to two calves in the group given the inactivated vaccine, compared with six in the negative controls (P = 0.05) and five in the group given the live vaccine. The mean virus excretion titres after the challenge were not significantly different between the groups. There was little seroconversion before the challenge, but six of the seven calves in the group given the inactivated vaccine showed significant seroconversion within two weeks after the challenge, compared with only one calf in each of the other two groups (P = 0.015).
Assuntos
Infecções por Vírus Respiratório Sincicial/veterinária , Vacinas contra Vírus Sincicial Respiratório/imunologia , Vírus Sincicial Respiratório Bovino/imunologia , Animais , Anticorpos Antivirais/imunologia , Anticorpos Antivirais/isolamento & purificação , Bovinos , Imunidade Materno-Adquirida/imunologia , Imunoglobulina G/sangue , Infecções por Vírus Respiratório Sincicial/imunologia , Vírus Sincicial Respiratório Bovino/isolamento & purificação , Vírus Sincicial Respiratório Bovino/patogenicidade , Vacinas de Produtos InativadosRESUMO
A commercially available inactivated vaccine against infectious bovine rhinotracheitis (BHV1) was tested to assess its ability to immunise young seronegative calves and protect them against challenge with a virulent strain of BHV1. Calves showed seroconversion after one or two doses of vaccine. A two-dose and three-dose vaccination regimen each afforded calves significant protection against challenge as judged by the development of clinical symptoms. Vaccinated calves were on average 7 to 10 kg heavier than control calves 24 days after challenge, a statistically significant difference. Vaccination had no significant effect on the virus excretion pattern after challenge.
Assuntos
Herpesvirus Bovino 1/imunologia , Rinotraqueíte Infecciosa Bovina/prevenção & controle , Vacinação/veterinária , Vacinas Virais , Animais , Anticorpos Antivirais/biossíntese , Peso Corporal , Bovinos , Herpesvirus Bovino 1/crescimento & desenvolvimento , Mucosa Nasal/microbiologia , Distribuição AleatóriaRESUMO
The absorption pattern of phenylbutazone was studied in five horses during administration of the drug in a paste formulation on days 1, 5, 8 and 12 of a 12-day dosing schedule. Since two or more plasma concentration peaks were usually obtained following each oral dose, it was concluded that phasic absorption was a particular feature of the oil:water formulation of the product. Possible causes of this unusual absorption pattern are discussed and the therapeutic implications of both phasic absorption and the recorded values of Cmax, tmax and AUC024 for phenylbutazone and its active metabolite oxyphenbutazone are considered.